Equities Analysts Set Expectations for ATOS FY2029 Earnings

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Equities research analysts at HC Wainwright issued their FY2029 EPS estimates for Atossa Therapeutics in a report released on Thursday, January 30th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.14) per share for the year. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share.

Several other analysts have also recently commented on ATOS. StockNews.com cut shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th. Ascendiant Capital Markets raised their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th.

Atossa Therapeutics Price Performance

Shares of NASDAQ:ATOS opened at $0.84 on Monday. The firm has a fifty day moving average price of $1.03 and a 200 day moving average price of $1.26. Atossa Therapeutics has a 1-year low of $0.72 and a 1-year high of $2.31. The stock has a market cap of $105.91 million, a P/E ratio of -3.83 and a beta of 1.26.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC increased its stake in shares of Atossa Therapeutics by 148.2% in the fourth quarter. SG Americas Securities LLC now owns 103,865 shares of the company’s stock valued at $98,000 after purchasing an additional 62,016 shares during the period. JPMorgan Chase & Co. boosted its holdings in Atossa Therapeutics by 177.1% during the third quarter. JPMorgan Chase & Co. now owns 149,642 shares of the company’s stock worth $227,000 after buying an additional 95,643 shares in the last quarter. Barclays PLC increased its holdings in shares of Atossa Therapeutics by 280.9% in the third quarter. Barclays PLC now owns 167,718 shares of the company’s stock valued at $255,000 after buying an additional 123,683 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Atossa Therapeutics by 1.6% in the third quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock valued at $4,278,000 after buying an additional 44,762 shares in the last quarter. Finally, XTX Topco Ltd lifted its position in shares of Atossa Therapeutics by 101.2% during the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after acquiring an additional 24,951 shares during the last quarter. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.